Aside from adrenal insufficiency and thyroid toxicities, how do you approach other hormonal imbalances during treatment with immune checkpoint inhibitors?   

A systematic review (Barroso-Sousa et al., PMID 28973656) indicated that hypophysitis can occur in 3.2% of patients treated with ipilimumab (Yervoy) and this increased to 6.4% when combined with nivolumab (Opdivo). Obviously, adrenal and thyroid functions need to be assessed first but other function...